Accordingly, abundance of glutamine, but not other SLC38A2 substrates, was increased in TIF from SLC38A2-deficient B16-OVA tumours (Extended Data Fig. 4j), further supporting that SLC38A2 more selectively mediates the transport of glutamine. The gene discussed is SLC38A2; the disease is neoplasm.